Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS

Status Active, not recruiting

Clinical Trial Summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder, which can cause arterial or venous thrombosis. The frequency of PNH in young patients (< 50 years old) with embolic stroke (ESUS), transient ischemic attack (ETUS) or superior sagittal sinus cerebral venous thrombosis (SSS-CVTUS) of undetermined source, is currently unknown. This study proposes to recruit ESUS, ETUS, SSS-CVTUS patients to determine the frequency of PNH diagnosis confirmed by flow cytometry in these patient populations.

Clinical Trial Description

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder leading to red blood cells hemolysis and thrombosis. PNH has been reported to be the cause of cerebral venous thrombosis and embolic ischemic strokes and is sometimes diagnosed after the ischemic event. In young patients with embolic ischemic stroke of undetermined source (ESUS), thrombophilia is usually investigated. However, access to PNH testing is limited. PNH is rarely investigated in stroke patients and its contribution to the pathophysiology of ESUS is unknown. The investigators hypothesize that this condition is underdiagnosed, resulting in potential preventive opportunities being lost, since PNH can be successfully treated. This observational study aims to determine the frequency of PNH among young (≤50 years old) patients with recent ESUS or embolic transient ischemic attacks (TIA) of undetermined source (ETUS) and patients with SSS-CVT of undetermined source (SSS-CVTUS). Patients with ESUS or ETUS will be first screened for: (a) evidence of hemolysis based on their plasma lactate dehydrogenase (LDH) levels, (b) unexplained anemia based on their hemoglobin (Hb) levels, and (c) unexplained cytopenia (e.g., neutropenia and thrombocytopenia). Flow cytometry analysis for PNH will be performed with blood samples collected from subjects with abnormal level of plasma LDH (1.5X ULN) or unexplained anemia or cytopenia. Patients with SSS-CVTUS will undergo flow cytometry without prior screening. In addition, plasma and DNA samples will be collected in an optional sub-study for future analysis of DNA mutations related to specific PNH phenotypes in patients with stroke. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03329365
Study type	Observational
Source	Lawson Health Research Institute
Contact
Status	Active, not recruiting
Phase
Start date	November 1, 2018
Completion date	March 29, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Not yet recruiting	`NCT03605355` - Feasibility Study on the Medical and Economic Consequences of Outpatient Management of TIAs and Minor Strokes
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT02905383` - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital	N/A
Completed	`NCT04078737` - Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II	Phase 3
Completed	`NCT02141932` - Pocket-size Cardiovascular Ultrasound in Stroke	N/A
Recruiting	`NCT01954329` - Markers in the Diagnosis of TIA	N/A
Completed	`NCT02011256` - Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack	N/A
Completed	`NCT01918891` - Center for Stroke Disparities Solution - Community Transitions Intervention	N/A
Recruiting	`NCT01526824` - Lovaza's Effect on Clopidogrel in a Neuro Population	Phase 0
Completed	`NCT01020851` - The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial	N/A
Completed	`NCT00597974` - Neurological Outcome With Carotid Artery Stenting	N/A
Completed	`NCT00211731` - Preventing Recurrent Stroke in Minority Populations	N/A
Active, not recruiting	`NCT03635749` - Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis	Phase 3
Completed	`NCT03153020` - Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône
Recruiting	`NCT04075500` - Optimal Detection of Atrial Fibrillation in TIA	N/A
Recruiting	`NCT06091319` - Florbetaben for Imaging of Vascular Amyloid
Completed	`NCT04604015` - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt	N/A
Completed	`NCT00885456` - Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT	Phase 2
Completed	`NCT05620966` - EEG to Diagnose TIA and Stroke

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.